Sharon Shacham
2021
In 2021, Sharon Shacham earned a total compensation of $3.1M as Chief Scientific Officer and Former President at Karyopharm Therapeutics, a 15% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $249,953 |
|---|---|
| Option Awards | $1,507,217 |
| Salary | $499,905 |
| Stock Awards | $832,832 |
| Other | $16,684 |
| Total | $3,106,591 |
Shacham received $1.5M in option awards, accounting for 49% of the total pay in 2021.
Shacham also received $250K in non-equity incentive plan, $499.9K in salary, $832.8K in stock awards and $16.7K in other compensation.
Rankings
In 2021, Sharon Shacham's compensation ranked 4,293rd out of 12,405 executives tracked by ExecPay. In other words, Shacham earned more than 65.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,293 out of 12,405 | 65th |
Division Manufacturing | 1,770 out of 5,494 | 68th |
Major group Chemicals And Allied Products | 740 out of 2,369 | 69th |
Industry group Drugs | 661 out of 2,090 | 68th |
Industry Pharmaceutical Preparations | 468 out of 1,537 | 70th |
Source: SEC filing on April 8, 2022.
Shacham's colleagues
We found five more compensation records of executives who worked with Sharon Shacham at Karyopharm Therapeutics in 2021.
2021
Richard Paulson
Karyopharm Therapeutics
Chief Executive Officer
2021
Michael Kauffman
Karyopharm Therapeutics
Chief Executive Officer
2021
Michael Mason
Karyopharm Therapeutics
Chief Financial Officer
2021
Jatin Shah
Karyopharm Therapeutics
Chief Medical Officer
2021
Ran Frenkel
Karyopharm Therapeutics
Executive Vice President, Chief Development Officer
News
Karyopharm Therapeutics CEO Richard Paulson receives $8.4M in 2021
April 8, 2022
Karyopharm Therapeutics CEO Michael Kauffman's 2020 pay jumps 22% to $3.9M
April 7, 2021
Karyopharm Therapeutics CEO Michael Kauffman's 2019 pay jumps 42% to $3.2M
April 9, 2020
Karyopharm Therapeutics Executive Vice President, Chief Commercial Officer Anand Varadan receives $2.3M in 2018
April 19, 2019